U.S. Banks Stock News

NYSE:FG
NYSE:FGInsurance

Assessing F&G Annuities & Life (FG) Valuation After Insider Buying And A US$100 Million Buyback Program

A recent insider purchase by director Celina J. Wang Doka, alongside a newly authorized US$100 million share repurchase program at F&G Annuities & Life (FG), has put fresh attention on the insurer's stock. See our latest analysis for F&G Annuities & Life. At around US$24.20, FG’s 6.84% 1 month share price return contrasts with a 25.10% 3 month share price decline and a 29.03% 1 year total shareholder return loss. This means recent buying interest follows a weak stretch where confidence has...
NYSE:MGM
NYSE:MGMHospitality

Is MGM Resorts International (MGM) Priced Right After Recent 1-Year 19.6% Return?

Wondering if MGM Resorts International at around US$36.32 is a bargain or just fairly priced? This article walks through what the current share price might be telling you about value. The stock has returned 2.7% over the last 7 days, while the 1-year return sits at 19.6% and the year-to-date move is a 0.5% decline, with longer 3- and 5-year periods also showing declines. Recent coverage has focused on MGM Resorts International as a key player in global gaming and hospitality, with attention...
NasdaqGS:LIVN
NasdaqGS:LIVNMedical Equipment

How FDA Approval of Aura6000 Sleep Apnea Therapy Will Impact LivaNova (LIVN) Investors

On 19 March 2026, LivaNova announced that the FDA granted premarket approval for its aura6000 System, a proximal hypoglossal nerve stimulation therapy for adult patients with moderate to severe obstructive sleep apnea who cannot use or benefit from first-line treatments like positive airway pressure. Backed by the rigorously designed OSPREY randomized controlled trial and plans for an MRI‑compatible, rechargeable next‑generation device, this approval opens a new neuromodulation avenue for...
NasdaqGS:AMGN
NasdaqGS:AMGNBiotechs

Amgen’s Repatha Data Reinforces Cardiovascular Franchise And Valuation Debate

Amgen (NasdaqGS:AMGN) released new VESALIUS-CV Phase 3 subgroup data on Repatha showing a significant reduction in first major cardiovascular events in high risk patients with diabetes. The results indicate that Repatha, used alongside statins or other LDL C lowering therapies, may support earlier intervention for patients without diagnosed atherosclerosis. These findings position Repatha as the only PCSK9 inhibitor with evidence across both primary and secondary prevention settings. For...
NasdaqGS:GLDD
NasdaqGS:GLDDConstruction

A Look At Great Lakes Dredge & Dock (GLDD) Valuation After Strong Recent Share Price Momentum

Why Great Lakes Dredge & Dock (GLDD) is on investors’ radar today Great Lakes Dredge & Dock (GLDD) has drawn fresh attention after a period of strong longer term share performance, including a past 3 months total return of 29.1% and a 1 year total return of 91.9%. See our latest analysis for Great Lakes Dredge & Dock. At a share price of $16.97, recent momentum has come through a strong 90 day share price return of 29.2% and a 1 year total shareholder return of 92%, pointing to improving...
NYSE:OMF
NYSE:OMFConsumer Finance

Is OneMain Holdings (OMF) Pricing Look Attractive After This Year’s Share Price Pullback

If you are wondering whether OneMain Holdings at around US$51.55 is offering fair value or a potential bargain, it helps to step back and look at the full valuation picture before making any decisions. The stock shows mixed recent returns, with a 0.1% move over the last 7 days, a 6.3% decline over 30 days, a 25.4% decline year to date, a 14.9% gain over 1 year, 79.3% over 3 years, and 48.9% over 5 years. Recent news coverage around OneMain Holdings has largely focused on its position within...
NYSE:VG
NYSE:VGOil and Gas

Does Venture Global (VG) Still Offer Value After Its Recent Share Price Surge?

If you are wondering whether Venture Global's current share price reflects its real worth, this article walks through the key numbers behind the stock. Over shorter periods the stock has been active, with returns of 10.9% over 7 days, 80.9% over 30 days, 149.0% year to date and 77.3% over the last year. These movements can affect how investors think about both upside potential and risk. Recent attention around Venture Global has centered on its role in the energy sector and how investors are...
NasdaqCM:BTBT
NasdaqCM:BTBTSoftware

Bit Digital (BTBT) Q4 Loss Of US$188 Million Tests Bullish Profitability Narratives

Bit Digital (BTBT) has just posted its FY 2025 numbers with Q4 total revenue of US$33.4 million and a basic EPS loss of US$0.58, set against trailing twelve month revenue of US$113.6 million and a TTM basic EPS loss of US$0.31. Over recent quarters the company has seen quarterly revenue move from US$25.6 million in Q4 2024 to US$33.4 million in Q4 2025. Basic EPS has swung between a loss of US$0.32 in Q1 2025 and a profit of US$0.48 in Q3 2025 before returning to a loss in Q4, leaving...
NasdaqGS:WIX
NasdaqGS:WIXIT

Has Wixcom (WIX) Rallied Too Far After Its Recent 23% Share Price Jump

If you are wondering whether Wix.com is attractively priced or still has more risk baked in than reward, the starting point is understanding what the current share price actually implies. The stock recently closed at US$87.14, after a sharp 23.7% gain over the last 30 days that sits against a 47.6% decline over the past year and a 70.3% decline over five years. That kind of rebound after a long stretch of weaker returns often comes after fresh information, such as changes in sentiment around...
NYSE:COMP
NYSE:COMPReal Estate

Compass (COMP) Valuation Check After Recent Share Price Weakness

Compass (COMP) has been drawing fresh attention after recent trading left the stock with a year-to-date return of about a 33% decline and a past 3-month move of roughly a 34% decline. See our latest analysis for Compass. The recent 1-day share price return of a 7.09% decline and 30-day share price return of a 27.38% decline at a latest share price of $7.08 sit against a 3-year total shareholder return of 119.20%, which hints that recent momentum has faded compared with earlier gains. If...
NYSE:UWMC
NYSE:UWMCDiversified Financial

UWM Holdings Tests Governance Stance With Bid For Two Harbors Servicing

UWM Holdings (NYSE:UWMC) has publicly challenged the management and board of Two Harbors as part of its acquisition proposal. The company is openly criticizing how Two Harbors is overseen, while outlining its interest in the firm's mortgage servicing portfolio. This move highlights UWM Holdings' acquisition ambitions and puts its leadership approach and governance views in the spotlight. For readers watching NYSE:UWMC, this public challenge comes at a time when the stock trades at $3.42 and...
NYSE:PBT
NYSE:PBTOil and Gas

Permian Basin Royalty Trust (PBT) Net Margin Compression Tests Bullish Narratives

Permian Basin Royalty Trust FY 2025 Earnings Snapshot Permian Basin Royalty Trust (PBT) has put up a mixed set of numbers for FY 2025 so far, with third quarter revenue at US$7.3 million and basic EPS of US$0.15, compared with US$8.4 million of revenue and EPS of US$0.17 in the same quarter a year earlier. Across the last six reported quarters, revenue has ranged from roughly US$3.1 million to US$8.8 million, while quarterly EPS has moved between US$0.05 and US$0.18. This gives a clear view...
NasdaqGM:DAVE
NasdaqGM:DAVEConsumer Finance

Assessing Whether Dave (DAVE) Shares Look Undervalued After Recent Volatility

Event context and recent share performance Dave (DAVE) has drawn investor attention after recent trading, with the stock last closing at US$174.95. The shares show a 2.3% decline over the past day and a 16.6% decline over the past week. See our latest analysis for Dave. While the recent 1-week share price return of a 16.6% decline and 90-day share price return of a 23.2% decline point to fading short term momentum, the 1-year total shareholder return of 106.9% and very large 3-year total...
NYSE:WCN
NYSE:WCNCommercial Services

Evaluating Waste Connections (WCN) Valuation After Recent Share Price Weakness

Why Waste Connections (WCN) Is On Investors’ Radar Recent share weakness in Waste Connections (WCN), including double digit negative returns over the past month and past 3 months, has turned more attention to whether the current price reflects its underlying fundamentals. See our latest analysis for Waste Connections. At a share price of US$156.02, Waste Connections has faced steady selling pressure recently, with a 30 day share price return of 9.36% and year to date share price return of...
NYSE:JPM
NYSE:JPMBanks

Is It Time To Reconsider JPMorgan Chase (JPM) After Recent Share Price Weakness?

If you are trying to work out whether JPMorgan Chase at about US$282.84 is offering good value or asking too much, it helps to break the story into what the market has been pricing in and what the fundamentals might support. The stock has seen a 1.3% decline over the last 7 days and a 5.8% decline over the last 30 days, while still showing a 13.1% decline year to date and an 18.9% return over the last year, with very large gains over 3 and 5 years of 133.0% and 109.0% respectively. Recent...
NasdaqGM:SIGA
NasdaqGM:SIGAPharmaceuticals

Does SIGA (SIGA)’s Repeat Special Dividend Reveal a Deeper Shift in Its Capital Allocation Priorities?

SIGA Technologies, Inc. recently announced that its board declared a special cash dividend of US$0.60 per share, payable on April 23, 2026, to shareholders of record as of April 7, 2026. The company linked this repeat special dividend to its strong balance sheet and its ongoing work with governments on smallpox preparedness amid geopolitical volatility. We’ll now examine how this repeat US$0.60 special dividend and the company’s emphasis on balance sheet strength shape SIGA’s investment...
NYSE:MC
NYSE:MCCapital Markets

Assessing Moelis (MC) Valuation After Recent Share Price Weakness

Moelis stock reaction and recent performance snapshot With no single headline event driving Moelis (MC) today, the current share price around US$54.28 and recent performance provide a reference point for thinking about risk, return, and timing. Over the past month the stock shows a return of about a 9% decline, with the past 3 months closer to a 24% decline, while the 1 year total return is roughly a 2% decline. Over the longer term, 3 year and 5 year total returns of about 62% and 31%...
NYSE:AXP
NYSE:AXPConsumer Finance

American Express Shareholder Votes Test Policies And Perceived Valuation Discount

American Express (NYSE:AXP) is set to face several shareholder proposals on political and healthcare policies at its upcoming annual meeting. Proposals call for oversight of political bias risk and for reporting and evaluation of the company’s coverage of transgender healthcare treatments for minors. The board has recommended that shareholders vote against these proposals, bringing governance and social policy questions into focus for investors. American Express, a major player in payments,...
NasdaqGS:RARE
NasdaqGS:RAREBiotechs

Is It Time To Reconsider Ultragenyx Pharmaceutical (RARE) After Its Prolonged Share Price Slump?

Wondering whether Ultragenyx Pharmaceutical at around US$19.38 is a bargain or a value trap? This breakdown will help you see what the current price is actually offering you. The stock has had a tough run, with returns of a 2.5% decline over 7 days, 17.1% decline over 30 days, 17.9% decline year to date, 48.8% decline over 1 year, and 51.7% and 82.9% declines over 3 and 5 years, which naturally raises questions about how the market is now viewing its prospects and risk. Recent share price...
NYSE:DFIN
NYSE:DFINCapital Markets

Assessing Donnelley Financial Solutions (DFIN) Valuation After Recent Share Pullback And Software Growth Expectations

Event context and recent share performance Donnelley Financial Solutions (DFIN) has drawn attention after a recent share move, with the stock closing at US$45.76. That level sits against a recent 8% decline over the past month and a smaller pullback over the past 3 months. See our latest analysis for Donnelley Financial Solutions. That recent pullback comes after a relatively flat year to date share price return of 0.28% and a 5 year total shareholder return of 57.63%. This suggests shorter...
NYSE:ENS
NYSE:ENSElectrical

Is It Too Late To Consider EnerSys (ENS) After An 86% One Year Share Price Rise

If you are wondering whether EnerSys at around US$171 per share is still reasonably priced or already stretched, a closer look at its valuation metrics can help clarify where it might sit on your watchlist. The stock has posted returns of 3.6% over the last 7 days, 3.1% over the past month, 13.7% year to date and 85.6% over the past year, with a 3 year return of 102.6% and 5 year return of 91.3% that many investors are weighing against the current price. Recent coverage of EnerSys has...
NasdaqGS:KHC
NasdaqGS:KHCFood

Is Kraft Heinz (KHC) Now An Opportunity After A 22.5% One Year Share Price Decline?

If you are wondering whether Kraft Heinz at around US$22.04 is a bargain or a value trap, you are not alone. The answer comes down to how you look at its valuation. The share price has moved 2.2% over the last 7 days, while returns over 30 days, year to date and the last year, at 10.4%, 9.6% and 22.5% declines, show that sentiment has been under pressure. Recent coverage has focused on how Kraft Heinz fits into the broader packaged food sector and how investors are weighing consumer brands...
NasdaqGS:NSIT
NasdaqGS:NSITElectronic

Is Insight Enterprises (NSIT) Share Slide Creating A Potential Valuation Opportunity Now

If you are wondering whether Insight Enterprises at US$65.82 is now pricing in too much pessimism or still has room to fall, the next step is to look closely at what the valuation actually says. The share price has recently been weak, with a 6.9% decline over 7 days, 21.2% over 30 days, 21.6% year to date and 56.9% over the past year. Recent headlines around Insight Enterprises have focused on the business as a listed technology name, which can shape how investors think about risk and...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Assessing Protagonist Therapeutics (PTGX) Valuation After Strong 1‑Year Shareholder Return

Why Protagonist Therapeutics Stock Is Drawing Attention Now Protagonist Therapeutics (PTGX) has been on investors’ radar after a recent share move, with the stock closing at US$98.97. Recent returns span a 7.5% gain over the past month and 12.6% over the past 3 months. See our latest analysis for Protagonist Therapeutics. While the share price slipped 3.1% in the last session to US$98.97, the 30 day share price return of 7.5% and 12.6% over 90 days sit alongside a 1 year total shareholder...